

New Hope on the Horizon: Advances in the Diagnosis and Treatment of **IDIOPATHIC HYPERSOMNIA**

MONDAY, JUNE 5 | 6:30 - 8:30 PM
JW MARRIOTT INDIANAPOLIS | JW GRAND BALLROOM 5



This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress.

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

PROGRAM OVERVIEW:

Idiopathic hypersomnia (IH) is a chronic neurological disorder that has significant impacts on daily functioning, with symptoms that include, but often go beyond excessive daytime sleepiness (EDS). Overall awareness about IH remains low, which contributes to the suboptimal recognition of this condition, which is often exacerbated by insufficient diagnostic criteria leading to delayed diagnosis and treatment. Until recently, there was no FDA approved treatment option for IH, and historically, although IH is not the same as narcolepsy, the same treatment options were offered, leading to suboptimal treatment response and exacerbation of disease burden. Recent advances, with a new option now approved and other agents in development, can help close some of the current gaps. This symposium will offer expert perspectives on the impact of IH, as well as best practices and advances for its screening, diagnosis, and treatment.

LEARNING OBJECTIVES:

After completing this activity, the participant should be better able to:

- Review the pathophysiology, definitions, and the burden of idiopathic hypersomnia (IH) on patients' quality of life.
- Summarize the clinical features and the current and emerging diagnostic parameters for IH.
- Discuss the burden of IH and practical approaches to assess the severity of IH symptoms.
- Describe conventional treatment options for IH and challenges with current treatments.
- Outline the rationale, efficacy and safety of new and emerging therapies for the treatment of IH.

FACULTY



Michael J. Thorpy, MD
Michael J. Thorpy, MD
Professor of Neurology
Albert Einstein College of Medicine
Director, Sleep-Wake Disorders Center
Department of Neurology
Montefiore Medical Center
Bronx, NY



Yves Dauvilliers, MD, PhD
Professor of Neurology and Physiology
University of Montpellier
Director, Sleep-Wake Disorders Centre
Department of Neurology
Gui de Chauliac Hospital
Montpellier, France

JOINT PROVIDERSHIP STATEMENT



In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

PHARMACY CONTINUING EDUCATION

PACE designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-23-149-L01-P. Type of activity: Application

HOW TO REQUEST CE CREDIT

An evaluation link will be emailed to all attendees after the symposium. We will send the evaluation link using the email you entered in the iPads provided during the meeting. Upon completion of the CME/CE evaluation, you will be able to print your certificate.

Several email reminders will be sent post-meeting. Please claim your credits by completing the evaluation by **Monday, June 12, 2023**.

For Pharmacists: Please allow 2-3 weeks after the June 12 deadline for your credit to be submitted to the CPE Monitor. For questions regarding the evaluation, please contact: cmhc_eval@cardiometabolichealth.org

DISCLOSURES

Planners and Managers

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The CMHC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Faculty

Dr. Dauvilliers discloses the following:

- Consultant: JAZZ, Takeda, orexia, Avadel, Idorsia

Dr. Thorpy discloses the following:

- Consultant/Advisory Board: Axsome, Balan

DISCLOSURE OF CONFLICT OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.